An open, single center, clinical investigation to evaluate the efficacy and safety of a non-hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal woman
Objective To evaluate the efficacy and safety of a non-hormonal vaginal moisturizer in alleviating the clinical symptoms of vulvovaginal atrophy (VVA).Methods This was an observational, single center, open label study in which the investigational product was applied to postmenopausal women (n = 36)...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Gynecological Endocrinology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09513590.2025.2500480 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850281744072179712 |
|---|---|
| author | Manuel Sánchez-Prieto Nicolás Mendoza Peter Chedraui Félix Lugo-Salcedo Aida Serra-Ribas Sonia Aladrén-Pérez Javier Bustos-Santafé Rafael Sánchez-Borrego |
| author_facet | Manuel Sánchez-Prieto Nicolás Mendoza Peter Chedraui Félix Lugo-Salcedo Aida Serra-Ribas Sonia Aladrén-Pérez Javier Bustos-Santafé Rafael Sánchez-Borrego |
| author_sort | Manuel Sánchez-Prieto |
| collection | DOAJ |
| description | Objective To evaluate the efficacy and safety of a non-hormonal vaginal moisturizer in alleviating the clinical symptoms of vulvovaginal atrophy (VVA).Methods This was an observational, single center, open label study in which the investigational product was applied to postmenopausal women (n = 36) with VVA symptoms three times per week for a period of 12 weeks. Patient’s perception of vaginal discomfort, sexual function improvement assessed with the Female Sexual Function Index (FSFI), quality of life evaluated with the Cervantes-SF scale, and subject’s satisfaction with the treatment were evaluated after 4 and 12 weeks of product use. In addition, vaginal health was evaluated with the Vaginal Health Index (VHI) score and the vaginal pH.Results A statistically significant decrease was observed in the severity of the most bothersome symptoms from moderate at baseline (mean 2.47 ± 0.55) to mild after 4 weeks (mean 1.33 ± 0.58) and 12 weeks (mean 1.32 ± 0.74, p < 0.0001). VHI scores significantly improved after 4 and 12 weeks compared to baseline (from 11.70 to 16.36 at 4 weeks and 17.34 at 12 weeks, both p < 0.0001). Vaginal pH decreased significantly from a mean pH of 6.27 ± 0.46 at baseline to 5.77 ± 0.59 at 4 weeks and 5.56 ± 0.60 at 12 weeks of treatment (p < 0.0001). Total FSFI scores significantly increased, indicating improvement of sexual function, after 4 and then after 12 weeks of product use (Baseline score 20.16 compared to 24.27 at 4 and 23.94 at 12 weeks, both p < 0.0001). Quality of life improved (decrease of total Cervantes-SF scores) after 12 weeks of product use as compared to baseline (Baseline 32.09 vs 26.45, p = 0.0004). At 12 weeks, a 97.5% reported overall satisfaction with the product and no adverse events related to the product were reported.Conclusion Through limited size study, the proposed non-hormonal vaginal moisturizer demonstrated being effective and safe for the management of VVA symptoms in postmenopausal women, offering significant improvements in symptom severity, vaginal health, sexual function, and quality of life. There is a need for further research with a larger sample and comparison with other similar products. |
| format | Article |
| id | doaj-art-2eb72e3dc4854a3a81ed0c36ee274fc6 |
| institution | OA Journals |
| issn | 0951-3590 1473-0766 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gynecological Endocrinology |
| spelling | doaj-art-2eb72e3dc4854a3a81ed0c36ee274fc62025-08-20T01:48:11ZengTaylor & Francis GroupGynecological Endocrinology0951-35901473-07662025-12-0141110.1080/09513590.2025.2500480An open, single center, clinical investigation to evaluate the efficacy and safety of a non-hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal womanManuel Sánchez-Prieto0Nicolás Mendoza1Peter Chedraui2Félix Lugo-Salcedo3Aida Serra-Ribas4Sonia Aladrén-Pérez5Javier Bustos-Santafé6Rafael Sánchez-Borrego7DiaTrecnon, Woman’s Clinic, Gynecology and Obstetrics, Teknon Medical Center, Barcelona, SpainDepartment of Obstetrics & Gynaecology, Faculty of Medicine, University of Granada, Granada, SpainDepartment of Obstetrics & Gynaecology, Faculty of Medicine, University of Granada, Granada, SpainDiaTrecnon, Woman’s Clinic, Gynecology and Obstetrics, Teknon Medical Center, Barcelona, SpainISDIN, Barcelona, SpainISDIN, Barcelona, SpainISDIN, Barcelona, SpainDiaTrecnon, Woman’s Clinic, Gynecology and Obstetrics, Teknon Medical Center, Barcelona, SpainObjective To evaluate the efficacy and safety of a non-hormonal vaginal moisturizer in alleviating the clinical symptoms of vulvovaginal atrophy (VVA).Methods This was an observational, single center, open label study in which the investigational product was applied to postmenopausal women (n = 36) with VVA symptoms three times per week for a period of 12 weeks. Patient’s perception of vaginal discomfort, sexual function improvement assessed with the Female Sexual Function Index (FSFI), quality of life evaluated with the Cervantes-SF scale, and subject’s satisfaction with the treatment were evaluated after 4 and 12 weeks of product use. In addition, vaginal health was evaluated with the Vaginal Health Index (VHI) score and the vaginal pH.Results A statistically significant decrease was observed in the severity of the most bothersome symptoms from moderate at baseline (mean 2.47 ± 0.55) to mild after 4 weeks (mean 1.33 ± 0.58) and 12 weeks (mean 1.32 ± 0.74, p < 0.0001). VHI scores significantly improved after 4 and 12 weeks compared to baseline (from 11.70 to 16.36 at 4 weeks and 17.34 at 12 weeks, both p < 0.0001). Vaginal pH decreased significantly from a mean pH of 6.27 ± 0.46 at baseline to 5.77 ± 0.59 at 4 weeks and 5.56 ± 0.60 at 12 weeks of treatment (p < 0.0001). Total FSFI scores significantly increased, indicating improvement of sexual function, after 4 and then after 12 weeks of product use (Baseline score 20.16 compared to 24.27 at 4 and 23.94 at 12 weeks, both p < 0.0001). Quality of life improved (decrease of total Cervantes-SF scores) after 12 weeks of product use as compared to baseline (Baseline 32.09 vs 26.45, p = 0.0004). At 12 weeks, a 97.5% reported overall satisfaction with the product and no adverse events related to the product were reported.Conclusion Through limited size study, the proposed non-hormonal vaginal moisturizer demonstrated being effective and safe for the management of VVA symptoms in postmenopausal women, offering significant improvements in symptom severity, vaginal health, sexual function, and quality of life. There is a need for further research with a larger sample and comparison with other similar products.https://www.tandfonline.com/doi/10.1080/09513590.2025.2500480Vulvovaginal atrophygenitourinary syndrome of menopausevaginal drynessdyspareuniamoisturizer |
| spellingShingle | Manuel Sánchez-Prieto Nicolás Mendoza Peter Chedraui Félix Lugo-Salcedo Aida Serra-Ribas Sonia Aladrén-Pérez Javier Bustos-Santafé Rafael Sánchez-Borrego An open, single center, clinical investigation to evaluate the efficacy and safety of a non-hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal woman Gynecological Endocrinology Vulvovaginal atrophy genitourinary syndrome of menopause vaginal dryness dyspareunia moisturizer |
| title | An open, single center, clinical investigation to evaluate the efficacy and safety of a non-hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal woman |
| title_full | An open, single center, clinical investigation to evaluate the efficacy and safety of a non-hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal woman |
| title_fullStr | An open, single center, clinical investigation to evaluate the efficacy and safety of a non-hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal woman |
| title_full_unstemmed | An open, single center, clinical investigation to evaluate the efficacy and safety of a non-hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal woman |
| title_short | An open, single center, clinical investigation to evaluate the efficacy and safety of a non-hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal woman |
| title_sort | open single center clinical investigation to evaluate the efficacy and safety of a non hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal woman |
| topic | Vulvovaginal atrophy genitourinary syndrome of menopause vaginal dryness dyspareunia moisturizer |
| url | https://www.tandfonline.com/doi/10.1080/09513590.2025.2500480 |
| work_keys_str_mv | AT manuelsanchezprieto anopensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT nicolasmendoza anopensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT peterchedraui anopensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT felixlugosalcedo anopensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT aidaserraribas anopensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT soniaaladrenperez anopensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT javierbustossantafe anopensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT rafaelsanchezborrego anopensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT manuelsanchezprieto opensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT nicolasmendoza opensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT peterchedraui opensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT felixlugosalcedo opensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT aidaserraribas opensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT soniaaladrenperez opensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT javierbustossantafe opensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman AT rafaelsanchezborrego opensinglecenterclinicalinvestigationtoevaluatetheefficacyandsafetyofanonhormonalvaginalmoisturizerforthesymptomatictreatmentofvulvovaginalatrophyinpostmenopausalwoman |